Compass Therapeutics Says FDA Recommended Survival Benefit Trial Before Tovecimig Approval Filing In Biliary Tract Cancer; Company Says New Trial Not Warranted
Share
Why It Matters
The FDA said Compass should run a survival test before seeking approval. Compass thinks that extra test is not necessary for their cancer drug.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.